TOP 1901 (Non-Small Cell Lung Cancer)

What is the Purpose of this Study?

This study is divided into 2 parts: a screening period and a study dosing period.

If you join this study, during the screening period you will:
- Have blood draws
- Visit the clinic for various tests to see if you’re eligible for the dosing period

If you're eligible for the dosing period, you will:
- Receive the study drugs atezolizumab and bevacizumab
- Come to the clinic clinic every 3 weeks to receive the study drugs
- Have blood draws
- Have imaging scans (CT and MRI)
What is the Condition Being Studied?
Non-Small Cell Lung Cancer (NSCLC)

Who Can Participate in this Study?

Adults age 18 or older who:

- Are diagnosed with EGFR mutant NSCLC

- Had their cancer get worse while receiving osimertinib

For more information about who can be in this study, please contact the study team.

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to find out how an experimental combination of drugs (atezolizumab + bevacizumab) works in your body and against your cancer.

Study Details

Full Title
Single arm phase 2 trial of atezolizumab and bevacizumab in Epidermal Growth Factor Receptor (EGFR) mutant non?small cell lung cancer in patients with progressive disease after receiving osimertinib (TOP 1901)
Principal Investigator

Protocol Number
IRB:
PRO00103723

NCT:
NCT04099836
ClinicalTrials.gov
View on ClinicalTrials.gov